BAIBYS raises $4.5M Series A for AI-based system that selects ideal sperm for fertility treatments | CTech
Summary
Israeli startup BAIBYS, which has developed an autonomous system for selecting ideal sperm for fertility treatments, aiming to improve treatment success rates and reduce birth defects, has announced the completion of its $4.5 million Series A funding round, led by Firstime Ventures, with participation from Japanese pharmaceutical giant ROHTO. Gal Golov and Dr. Yaron Silberman serve as co-CEOs of the company, which currently employs eight full-time workers at its offices in Ramat Hahayal, Tel Aviv, as well as several part-time employees and expert consultants in their respective fields.According to the World Health Organization (WHO), in a man with healthy sperm, 96% of sperm cells are abnormal. However, this process is not feasible for widespread clinical adoption due to its time-consuming nature, subjectivity, the requirement for extensive training, and consequently high cost. The system then operates autonomously for several minutes until the selection process is complete.The new partnership, which is not only financial, with a significant corporation like RHOTO opens up enormous possibilities for us in terms of marketing, R&D, and other areas, said Dr. Yaron Silberman, CEO of BAIBYS. In the coming months, we will pass significant milestones, with the crowning achievement being the start of sales in Europe later this year, assisted by our seed round investors and their network.